Company to host Virtual Investor Meeting on June 22, 2020

Company to host Virtual Investor Meeting on June 22, 2020  

, /PRNewswire/ -- CBD products have become more popular and well-known because of their lack of psychoactive effects many associate with cannabis. For example, in a conducted by HelloMD and Brightfield Group, approximately 60% out of 2,400 patients said that CBD participants used the compound to successfully treat insomnia or other sleep problems. , 42% percent of CBD users stopped using traditional medications and now use cannabis instead, and 80% of CBD users found CBD be very or extremely effective for treatment. Furthermore, CBD products such as full-spectrum oils also provide additional properties such as essential nutrients. In all, full-spectrum CBD is said to provide consumers with protein, fiber, and essential fatty acids. The oil also contains all 20 amino acids, including the nine essential amino acids that the human body processes on its own. Additionally, the full-spectrum oil contains vitamins A, C, E, and B complex. Yet despite extensive research, the FDA has only approved one cannabis-based drug, Epidolex, which is used to treat epilepsy. Nevertheless, thousands of retailers and ecommerce platforms have already began selling CBD products after the passage of the U.S. Farm Bill in 2018. Now, psychedelic products may follow a similar path to legalization. Newleaf Brands Inc. (OTC: NLBIF) (CSE: NLB), Canopy Growth Corporation (NYSE: CGC) (TSX: WEED), Tilray, Inc. (NASDAQ: TLRY), Aphria Inc. (NYSE: APHA) (TSX: APHA), Aurora Cannabis Inc. (NYSE: ACB)